

# The MESA heart failure risk score: can't we do more?

Jennifer E Ho,<sup>1,2</sup> Jared W Magnani<sup>1,2</sup>

In 1987, Framingham Heart Study pioneer Dr William B Kannel<sup>1</sup> wrote, 'Epidemiologic data on incidence and prognosis of cardiac failure in the general population are actually quite sparse.' Dr Kannel proceeded to report risk factors for heart failure identified in Framingham that included hypertension, ECG LV hypertrophy, obesity, diabetes, radiographic cardiac enlargement and cigarette use. Over the last decades heart failure epidemiology has been informed by advances in cardiac imaging, identification of novel biomarkers and refinements in pathophysiology and classification.

The exposures listed by Dr Kannel remain salient to heart failure risk. However, many individuals develop cardiovascular disease even in their absence. Risk assessment is refined by the integration of imaging, biomarkers and novel assessments. Risk scores are fundamental and essential for advancing risk prediction, and serve multiple functions to enhance epidemiological and clinical assessment. First, risk scores provide an avenue to integrate established exposures with novel, contemporary assessments in risk quantification. Second, risk scores may target at-risk populations and refine clinical definitions—such as 'stage A' and 'stage B' heart failure, for example—with the goal of disease prevention. Third, individualised risk scores can provide personal assessments of risk, be a tool for patient education or focus efforts to optimise prevention. Ultimately, the utility of a risk score is determined by its clinical relevance: can it be employed to target preventive strategies in heart failure, and 'turn back the clock' for a disease where the median survival upon diagnosis is as dismal as 5 years?<sup>2</sup> Is it relevant to diverse populations? Can the addition of novel imaging or biomarkers be implemented in a cost-effective manner?

To our knowledge, three major, observational, community-based cohort studies have published heart failure risk scores. In 1999, Kannel *et al*<sup>3</sup> described the probability of heart failure in Framingham participants with coronary disease, hypertension or valvular heart disease. The study did not include biomarkers or imaging aside from the chest radiograph, limiting its contemporary applicability, and preceded the advent of classification and discrimination, recognised now as essential for critically evaluating risk functions.<sup>4</sup> The Framingham score was tested in the Dynamics of Health, Aging and Body Composition (Health ABC) study.<sup>5</sup> Strengths of the model included the cohort's biracial design and enrolment of older adults, a population at increased heart failure risk. It is no surprise that the Framingham risk model had limited risk discrimination (C-statistic <0.70) in Health ABC; risk models translate poorly across cohorts with different designs, covariate measurement, and event ascertainment and adjudication. More recently, Atherosclerosis Risk in Communities (ARIC) Study investigators derived an ARIC heart failure risk model and tested the Framingham and Health ABC functions.<sup>6</sup> The results are telling: first, the heart failure risk score derived in ARIC was very robust (C-statistic=0.80). Second, the Framingham and Health ABC scores performed better with estimates derived in the ARIC cohort, rather than those published with the original cohort data. Third, all three risk scores improved in ARIC with the inclusion of N-terminal B-type natriuretic peptide (BNP). A consistent lesson is that scores perform better in their derivation cohort. The selected characteristics of the heart failure risk scores described are summarised in [table 1](#).

The most recent articulation of a heart failure risk is presented by Chahal *et al*.<sup>7</sup> They present a novel score developed from the Multi-Ethnic Study of Atherosclerosis (MESA) Study in over 6600 MESA participants. The score includes readily accessible covariates that have survived application in the other heart failure risk scores. MESA's ethnic and racial diversity enhances this heart failure score. We commend Chahal *et al* for a cogent discussion that situates MESA's ethnic/racial composition

in the context of the other risk scores cited here.

A fundamental strength of the presentation by Chahal *et al* consists in presenting nested models that integrate biomarker and imaging assessments. In separate models, the investigators determined the relative contributions of BNP and LV mass index (LVMI) as quantified by cardiac magnetic resonance. Presenting the comprehensive data with and without these assessments is noteworthy; such an approach provides a transparent evaluation of how assessments bolster risk prediction. The addition of BNP improved the C-statistic from 0.80 for the baseline model to 0.87 with its inclusion. Net reclassification improvement (NRI) was similarly enhanced (0.37, CIs not provided in manuscript). Interestingly, while the model was strengthened with the addition of LVMI, adding LVMI on top of BNP yielded only modest improvement. However, adding BNP to a model with LVMI yielded a 15% NRI (CIs not provided). The take-home is that BNP emerged a critical and salient contributor towards heart failure risk prediction.

We would like to suggest several limitations with the presentation by Chahal *et al*. The follow-up duration is shorter than that of the other scores described here, likely limiting the number of identified cases. The Framingham study employed cross-sectional pooling to evaluate 4-year risk windows, leveraging decades of follow-up. The ARIC score identified a heart failure incidence of 11% during a 15.5-year follow-up. In contrast, the present study identified a 3% event incidence. Heart failure develops insidiously, so we expect more cases will be identified prospectively as subclinical disease becomes more manifest in the MESA cohort. An argument could be made for pursuing another iteration of this project as the cohort ages. Second, the investigators present race-specific estimates of discrimination. However, the absence of NRI, likely because of the small number of events, renders the data difficult to interpret. Hence, the race-specific generalisability of the MESA heart failure risk score, as the authors acknowledge, is limited. Third, individuals with prevalent cardiovascular disease were excluded from MESA, limiting generalisability to those with established increased risk for developing heart failure. In contrast, the Framingham and Health ABC risk scores were developed in higher-risk cohorts. We suggest that the approaches are complementary; risk score development across varied cohorts improves our understanding of heart failure risk. A final limitation

<sup>1</sup>Department of National Heart, Lung and Blood Institute's and Boston University's Framingham Heart Study, Framingham, Massachusetts, USA; <sup>2</sup>Section of Cardiovascular Medicine, Department of Medicine, Boston University, Boston, Massachusetts, USA

**Correspondence to** Dr Jared W Magnani, Section of Cardiovascular Medicine, Boston University School of Medicine, 88 E. Newton Street, Boston 02118, MA, USA; jmagmagnani@bu.edu

**Table 1** Summary characteristics of the major, cohort-based heart failure risk scores

Cohort	Year published	Heart failure definition	Risk-window (years)	Risk factors included in base model	Summary findings	Major strengths	Selected limitations
Framingham Heart Study <sup>3</sup>	1999	Symptoms, physical exam features Radiography	4	Age, ECG LVH, heart rate, systolic BP, CHD, valvular disease, diabetes, with and without radiographic cardiomegaly and vital capacity	Publication of regression coefficients Articulation of risk profile with point scoring	Broad age range (45–94 years) Long-term follow-up (38 years) Pooled regression model Heart failure adjudication	Racially homogenous cohort Absence of biomarker or imaging assessments No discrimination or reclassification metrics Generalisability (CHD, hypertension, valvular heart disease)
Health ABC <sup>5</sup>	2008	Overnight hospitalisation	5	Age, CHD, ECG LVH, heart rate, systolic BP, albumin, creatine, glucose, smoking	C-statistic 0.73 Framingham Heart Study score C-statistic <0.70	Older adults Biracial (black and white race) Internal validation	Heart failure determination by hospitalisation only Misclassification of baseline covariates Cohort size (n=2853) Generalisability (cohort is black and white race)
Atherosclerosis Risk in Communities Study <sup>6</sup>	2012	ICD-9 coding, hospitalisation or death certificates	10	Age, sex, race, heart rate, systolic BP, CHD, antihypertensive medication, diabetes, BMI, smoking, log NT-BNP	C-statistic 0.80 (without NT-BNP) C-statistic 0.81 (with inclusion of NT-BNP)	Inclusion of BNP Biracial (black and white race) 15.5-year follow-up Covariate range	Heart failure ascertainment by hospitalisation, death certificate Generalisability (cohort is black and white race)
Multi-Ethnic Study of Atherosclerosis <sup>7</sup>	2014	Self-report and medical record	5	Age, sex, race and ethnicity, heart rate, systolic BP, diabetes, BMI, smoking, cholesterol, creatine, with and without log NT-BNP and LVMI	C-statistic 0.80 (without NT-BNP) C-statistic 0.87 (with inclusion of NT-BNP) Significant reclassification (25%–37%) with addition of LVMI or BNP	Multiethnic design Inclusion of BNP and LVMI Covariate range	Follow-up duration (median 4.7 years) with low heart failure incidence Younger-aged cohort Limited events, precluding race-specific risk score development

BMI, body mass index; BP, blood pressure; CHD, coronary heart disease; Health ABC, Dynamics of Health, Aging and Body Composition; ICD-9, *International Classification of Diseases*; LVH, LV hypertrophy; LVMI, LV mass index; NT-BNP, N-terminal B-type natriuretic peptide.

is the absence of external validation. The C-statistic of the final risk score was exceptionally high. It would be important to validate the performance of the MESA model in an external population. Cross-cohort development and validation of a heart failure risk score will enhance the impact and relevance of the product. Lastly, the NRI is perhaps less meaningful, since no universally accepted categories exist with respect to heart failure risk, and thus no change in treatment is prompted. Further, the use of four risk categories can increase reclassification, thereby inflating the NRI, again highlighting the importance of external validation. Furthermore, a ‘very high’ risk category, defined as >20% heart failure risk, is likely superfluous.

More than an academic exercise, deriving generalisable, novel risk scores has significant potential to enhance prevention. A primary objective of the analysis presented by the MESA investigators is a model informed by variables available in the primary care setting. The authors describe the tool as applicable towards motivating ‘both patients and physicians’ to target modifiable risk factors. We applaud the implication of a partnership between the patient and physician to modify and address risk.

We are far from done with heart failure risk prediction. The fundamental question still remains: what is the clinical utility of a heart failure risk score? We can learn from the application of risk scores to cardiovascular disease prevention in general and their utility in identifying the at-risk patient. Can a similar preventive strategy be guided by a heart failure risk score? The St Vincent’s Screening to Prevent Heart Failure Study recently randomised 1374 patients free of heart failure to usual care versus screening with BNP testing and showed reduced rates of LV systolic and diastolic dysfunction and clinical heart failure after a 4.2-year follow-up.<sup>8</sup> We believe that similar future studies are needed to test the direct clinical relevance of risk scores to disease prevention. Future studies of heart failure risk may also consider distinguishing separate risks for preserved and reduced ejection fraction. The presentations and disease course differ between the two and merit the development of specific risk functions. Second, multiple biomarkers have been associated with heart failure. High-sensitivity troponin, soluble-ST2 and galectin-3 are examples. As such markers become more mainstream, their inclusion will be important even in the ‘parsimonious model,’ as the MESA authors describe their heart failure risk score, in order to

evaluate their contributions. Third, the MESA heart failure risk score is the fourth such score to our knowledge developed in a community-based cohort. We would argue that the time has come for cardiovascular risk prediction to move beyond the individual cohort. A well-designed multicohort heart failure risk score would have increased generalisability and facilitated conducting the race-specific and ethnic-specific approaches that could not be undertaken in the MESA analysis. In conclusion, the current era has seen epidemiology face increasing emphasis on how it can modify public health. Risk scores are informative at the cohort level, and the study by Chahal *et al* is a substantive contribution to this literature. We now need to demonstrate that the heart failure risk score can be applied towards disease prevention.

**Contributors** JEH and JWM participated in the drafting of this editorial and take full responsibility for its content.

**Competing interests** This work was supported by grants from the National Institute of Health to JWM

(1R03AG045075) and to JEH (K23-HL116780). JWM and JEH are further supported by Boston University School of Medicine Department of Medicine Career Investment Awards.

**Provenance and peer review** Commissioned; internally peer reviewed.



CrossMark

**To cite** Ho JE, Magnani JW. *Heart* 2015;**101**:7–9.

Published Online First 11 November 2014



► <http://dx.doi.org/10.1136/heartjnl-2014-305697>

*Heart* 2015;**101**:7–9.  
doi:10.1136/heartjnl-2014-306459

## REFERENCES

- 1 Kannel WB. Epidemiology and prevention of cardiac failure: Framingham Study insights. *Eur Heart J* 1987;**8**(Suppl F):23–6.

- 2 Lloyd-Jones D, Adams RJ, Brown TM, *et al*. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. *Circulation* 2010;**121**:e46–215.
- 3 Kannel WB, D'Agostino RB, Silbershatz H, *et al*. Profile for estimating risk of heart failure. *Arch Intern Med* 1999;**159**:1197–204.
- 4 Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, *et al*. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. *Stat Med* 2008;**27**:157–72; discussion 207–12.
- 5 Butler J, Kalogeropoulos A, Georgiopoulou V, *et al*. Incident heart failure prediction in the elderly: the health ABC heart failure score. *Circ Heart Fail* 2008;**1**:125–33.
- 6 Agarwal SK, Chambless LE, Ballantyne CM, *et al*. Prediction of incident heart failure in general practice: the Atherosclerosis Risk in Communities (ARIC) Study. *Circ Heart Fail* 2012;**5**:422–9.
- 7 Chahal H, Bluemke D, Wu C, *et al*. Heart failure risk prediction in community dwelling adults: the Multi-Ethnic Study of Atherosclerosis Study. *Heart* 2015;**101**:58–64.
- 8 Ledwidge M, Gallagher J, Conlon C, *et al*. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. *JAMA* 2013;**310**:66–74.